Effect of Prophylactic Embolization on Patients With Blunt Trauma at High Risk of Splenectomy
A Randomized Clinical Trial

Catherine Arvieux, MD, PhD; Julien Frandon, MD, PhD; Fatah Tidadini, MSc; Valérie Monnin-Bares, MD; Alison Foote, PhD; Vincent Dubuisson, MD; Emilie Lermite, MD, PhD; Jean-Stéphane David, MD, PhD; Frederic Douane, MD; Christophe Tresallet, MD, PhD; Marie-Christine Lemoine, MD, PhD; Mathieu Rodiere, MD; Pierre Bouzat, MD, PhD; Jean-Luc Bosson, MD, PhD; Antoine Vilotitch, MSc; Sandrine Barbois, MD; Frédéric Thony, MD; for the Splenic Arterial Embolization to Avoid Splenectomy (SPLASH) Study Group

IMPORTANCE Splenic arterial embolization (SAE) improves the rate of spleen rescue, yet the advantage of prophylactic SAE (pSAE) compared with surveillance and then embolization only if necessary (SURV) for patients at high risk of spleen rupture remains controversial.

OBJECTIVE To determine whether the 1-month spleen salvage rate is better after pSAE or SURV.

DESIGN, SETTING, AND PARTICIPANTS In this randomized clinical trial conducted between February 6, 2014, and September 1, 2017, at 16 institutions in France, 133 patients with splenic trauma at high risk of rupture were randomized to undergo pSAE or SURV. All analyses were performed on a per-protocol basis, as well as an intention-to-treat analysis for specific events.

INTERVENTIONS Prophylactic SAE, preferably using an arterial approach via the femoral artery, or SURV.

MAIN OUTCOMES AND MEASURES The primary end point was an intact spleen or a spleen with at least 50% vascularized parenchyma detected on an arterial computed tomography scan at 1 month after trauma, assessed by senior radiologists masked to the treatment group. Secondary end points included splenectomy and pseudoaneurysm, secondary SAE after inclusion, complications, length of hospital stay, quality-of-life score, and length of time off work or studies during the 6-month follow-up.

RESULTS A total of 140 patients were randomized, and 133 (105 men [78.9%]; median age, 30 years [interquartile range, 23-47 years]) were retained in the study. For the primary end point, data from 117 patients (57 who underwent pSAE and 60 who underwent SURV) could be analyzed. The number of patients with at least a 50% viable spleen detected on a computed tomography scan at month 1 was not significantly different between the pSAE and SURV groups (56 of 57 [98.2%] vs 56 of 60 [93.3%]; difference, 4.9%; 95% CI, −2.4% to 12.1%; P = .37). By the day 5 visit, there were significantly fewer splenic pseudoaneurysms among patients in the pSAE group than in the SURV group (1 of 65 [1.5%] vs 8 of 65 [12.3%]; difference, −10.8%; 95% CI, −19.3% to −2.1%; P = .03), significantly fewer secondary embolizations among patients in the pSAE group than in the SURV group (1 of 65 [1.5%] vs 19 of 65 [29.2%]; difference, −27.7%; 95% CI, −41.0% to −15.9%; P < .001), and no difference in the overall complication rate between the pSAE and SURV groups (19 of 65 [29.2%] vs 27 of 65 [41.5%]; difference, −12.3%; 95% CI, −28.3% to 4.4%; P = .14). Between the day 5 and month 1 visits, the overall complication rate was not significantly different between the pSAE and SURV groups (11 of 59 [18.6%] vs 12 of 63 [19.0%]; difference, −0.4%; 95% CI, −14.4% to 13.6%; P = .96). The median length of hospitalization was significantly shorter for patients in the pSAE group than for those in the SURV group (9 days [interquartile range, 6-14 days] vs 13 days [interquartile range, 9-17 days]; P = .002).

CONCLUSIONS AND RELEVANCE Among patients with splenic trauma at high risk of rupture, the 1-month spleen salvage rate was not statistically different between patients undergoing pSAE compared with those receiving SURV. In view of the high proportion of patients in the SURV group needing SAE, both strategies appear defendable.

TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02021396

Published online September 16, 2020.

© 2020 American Medical Association. All rights reserved.

Author Affiliations: Author affiliations are listed at the end of this article.

Group Information: The members of the study for Splenic Arterial Embolization to Avoid Splenectomy (SPLASH) study group appear at the end of the article.

Corresponding Author: Catherine Arvieux, MD, PhD, Department of General and Digestive Surgery, CHU Grenoble Alpes, CS 10232, 38043 Grenoble Cedex 09, France (carvieux@chu-grenoble.fr).
The spleen is the organ most frequently affected in the event of blunt abdominal trauma, with an incidence of approximately 40,000 splenic traumas per year in the United States. In 10% to 20% of splenic trauma cases, the patient is admitted in a state of hemorrhagic shock and requires immediate surgical management with, in most cases, hemostatic splenectomy. Complications of splenectomy are either immediately postoperative or lifelong, principally fulminating infections for which the occurrence is 100 times higher than that in individuals who did not undergo splenectomy. In the approximately 85% of patients who are hemodynamically stable on arrival, the aim is to obtain the best splenic rescue rate. Nonoperative management of splenic trauma has been recommended for 20 years, but, in practice, secondary splenectomy owing to hemorrhage is often needed. The final rate of spleen rescue was only 60% in a major retrospective review of the trauma experience in east coast US centers prior to the era of embolization.

The development of splenic arterial embolization (SAE) in expert trauma centers has increased the rate of spleen rescue to more than 80%, and it has been shown that trauma centers with high rates of angiography have a lesser incidence of splenectomy in the management of blunt splenic injury than elsewhere. However, for the most part, these results come from retrospective series, and the question of operative vs nonoperative management of splenic trauma has never been rigorously evaluated in a randomized clinical trial, to our knowledge. Splenic arterial embolization is not free of complications and has a failure rate of up to 30%. The risk factors for complications are not yet well established. As for any organ, the current internationally accepted indication for SAE is the presence of an active leak of contrast medium detected on a computed tomography (CT) scan, but in view of its efficacy, expert centers have extended the indication for embolization to patients who have predisposing factors for secondary splenic hemorrhage that have been well identified in retrospective series: splenic pseudoaneurysms (SPAs) and splenic arteriovenous fistulas (SAVFs), a large hemoperitoneum, and severe damage (American Association for the Surgery of Trauma Organ Injury Scale [OIS] grade 3-5). In these situations, the failure rate of nonoperative treatment is greater than 50%. Owing to the greater than 80% risk of secondary rupture, preventive embolization of SPAs and SAVFs is currently performed as routine practice, as recommended by US and international guidelines and, ethically, cannot be questioned in a randomized clinical trial; nevertheless, for patients at high risk of secondary splenic hemorrhage, such as a large hemoperitoneum and severe damage, practices are still very heterogeneous.

Owing to the relatively high incidence of splenic trauma, it is important that the potential benefits and risks of SAE are clearly defined. In the present multi-institutional randomized clinical trial (NCT02021396), our hypothesis was that prophylactic SAE (pSAE) would improve the rate of spleen rescue at 1 month compared with surveillance alone followed by embolization only if necessary (SURV) among hemodynamically stable adult patients with severe splenic trauma at high risk of splenectomy. Secondary goals were to evaluate the adverse effects of pSAE compared with SURV at day 5, month 1, and month 6.

### Methods

**Design, Setting, and Participants**

This was a prospective randomized multicenter clinical trial (trial protocol in Supplement 1). Patients admitted via the emergency department, shock treatment unit, or intensive care unit or for surgery in 1 of the 16 participating level 1 trauma centers throughout France between February 6, 2014, and September 1, 2017, were screened. Each participating institution provided institutional review board approval of the study protocol, and each patient, or their legal representative, provided written informed consent before participation. This study followed the Consolidated Standards of Reporting Trials (CONSORT) reporting guideline.

Adult (≥18 years) hemodynamically stabilized patients (according to the French Society of Anesthesia & Intensive Care Medicine criteria) with blunt splenic trauma that had occurred within the previous 48 hours and spleen damage with high risk of splenectomy assessed by injected abdominal CT were enrolled and randomized to receive pSAE or SURV. Inclusion criteria were either OIS grade 3 spleen trauma with a large pelvic hemoperitoneum (defined as large if there was perisplenic effusion associated with pelvic effusion) and/or serious damage with a New Injury Severity Score of 15 or more; OIS grade 4 spleen trauma; or OIS grade 5 spleen trauma with persisting vascularization of the spleen.

Unstable patients, patients with OIS grade 5 shattered spleen, and patients who were stable but immediately needed embolization of the spleen or another organ (ie, an active leak and/or SPA or SAVF detected on the initial CT scan) were excluded.

To avoid classification bias, a preliminary consensus meeting of radiologists from participating centers was organized before the launch of the study to agree on definitions and provide specific training in grading splenic trauma OIS detected on CT scans (see consensus definitions in the eAppendix in Supplement 2). Moreover, assessment of all CT scans was performed by 2 expert radiologists (J.F. and V.M.-B.) who were
blinded to the randomization group. If they both disagreed with the OIS classification proposed by the enrolling center, the patient was excluded. If 1 radiologist disagreed, a third assessment was made by a senior expert, and the patient was included or excluded. Records were kept in each center of the characteristics of eligible, included, and excluded patients (eTable 1 in Supplement 2).

Randomization and Masking
Included patients were randomly assigned in a 1:1 ratio to undergo either pSAE or SURV. Randomization was performed with stratification according to center. Centralized randomized assignment was performed electronically. Neither the patients nor their clinicians were blinded to treatment assignment. Both the criteria for inclusion (day 0) and the primary end point (month 1) were validated by 2 senior radiologists (J.F. and V.M.-B.) blinded to the treatment assignment.

Study Treatment
For pSAE, an arterial approach via the femoral artery was preferred, or, for patients with unfavorable anatomy, a humeral approach via the celiac trunk, using a maximum 6F catheter, was preferred. The choice of catheterization equipment was at the discretion of the operator. Rigid coils of 0.089 cm (0.035 in) were preferred to reduce the risk of emboli migration. The use of microcoils was discouraged, and the use of glue, gelatin fragments, or microparticles was prohibited, as described in the eFigure in Supplement 2. Proximal or combined proximal and distal splenic artery embolization was required (eFigure in Supplement 2).

Assessments
Before enrollment and randomization, each patient underwent a baseline evaluation consisting of medical history taking and a physical examination (including age, sex, OIS splenic injury severity grade, and New Injury Severity Score trauma severity). In routine practice, all hemodynamically stable patients with abdominal trauma underwent a whole-body multibarrel CT scan with contrast injection at admission. Patients with a history of allergy or demonstrated intolerance to iodine were treated using the antiallergic equipment in use in the hospital. The admission CT scan included abdominal pelvic sections without injection, and then, after opacification, at arterial and parenchymal times (60-90 seconds). The quantity of iodine injected was at least 1 mL/kg at a concentration of 300 to 350 mg/mL. The imaging data collected during the study (CT scans and embolization) on CD or DVD were archived in a centralized and secure archiving system. For included patients, the medical evaluation, an assessment of complications, and whole-body multibarrel CT scans with contrast injection were repeated at day 5 (−1 day/+3 days) while the patient was still hospitalized and at 1 month and 6 months after enrollment. Management of patients followed the French28 and international guidelines, including the prevention of thromboembolic complications. Unplanned SAE was performed in the event of clinical deterioration and/or an urgent indication according to consensus recommendations. The amount of time a patient was off work or studies were interrupted (many patients were students) was noted. The duration of hospitalization and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score (a patient-reported functional activity score, where 0 corresponds to no impairment and 96 [the maximum score] corresponds to severe handicap) were recorded at each follow-up visit.

End Points
The primary end point was the composite criterion of a spleen with at least 50% vascularized parenchyma detected on the arterial CT scan and no splenectomy at the 1-month postinclusion visit, assessed by senior radiologists (J.F. and V.M.-B.) masked to the study group. Secondary end points included death; splenectomy; vascular spleen abnormalities; need for urgent embolization or reembolization; hemorrhagic, infectious, and thromboembolic complications; length of hospital stay; spleen rescue rate at 6 months; total time off work or studies; and physical activity. Criteria for complications are listed in eTable 2 in Supplement 2.

Sample Size Calculation
Assuming an expected rate of splenectomy (or rate of spleen necrosis) of 60% in the SURV group and 10% in the SAE group and a 5% α risk and 20% β risk, 120 evaluable patients (60 in each group) were required. Thus, 140 patients were to be included with a maximal number misclassified and with 15% of images lost at 1 month.

Statistical Analysis
All analyses were performed on a per-protocol basis, as well as an intention-to-treat analysis for specific events. For all descriptive analyses, median values and interquartile ranges (IQRs) are given for continuous variables, and numbers and percentages are given for categorical variables. For categorical variables, the χ2 test was used to compare the 2 randomization groups, considering the Cochran criteria. If these were not validated, a nonparametric Fisher exact test was used. Continuous parameters were analyzed using the t test, or the Mann-Whitney test if normal distribution was not (graphically) validated. For the primary end point, a sensitivity analysis was performed using multiple imputation (10 imputations) of missing data in a simple logistic regression to validate the result. Confidence intervals for the difference of proportions were calculated using the Fisher z approximation. All P values were from 2-sided tests and results were deemed statistically significant at P < .05. Statistical analysis was performed using Stata, version 15 software (StataCorp).

Results
Study Patients
A total of 663 patients presented with splenic trauma in the 16 participating French level 1 trauma centers, of whom 140 eligible patients were enrolled in an emergency context and randomized to undergo immediate pSAE (n = 71) or SURV alone (n = 69). Seven patients were subsequently found to meet the exclusion criteria and were excluded from the study (Figure 1).

Figure 1
Effect of Prophylactic Embolization on Trauma Patients at High Risk of Splenectomy

The baseline characteristics of the remaining 133 patients were well balanced between the groups (Table 1).\(^2\)\(^2\)\(^3\)\(^9\)\(^3\)\(^3\)

**Primary End Point**

For the primary end point, the number of patients with at least 50% viable spleen detected on the CT scan at month 1 was not significantly different between the pSAE and SURV groups detected at day 5 (19 of 65 [29.2%] vs 27 of 65 [41.5%]; difference, −12.3%; 95% CI, −28.3% to 4.4%; \(P = .14\)), between day 5 and month 1 (11 of 59 [18.6%] vs 12 of 63 [19.0%]; difference, −0.4%; 95% CI, −14.4% to 13.6%; \(P = .96\) (Table 3), or at the month 1 visit (eTable 4 in Supplement 2).

**Overall Mortality and Morbidity**

One patient from the SURV group died before the day 5 visit of cranial trauma (1 of 133 [0.8%]). There was no significant difference in the overall complication rate between the pSAE and SURV groups detected at day 5 (19 of 65 [29.2%] vs 27 of 65 [41.5%]; difference, −12.3%; 95% CI, −28.3% to 4.4%; \(P = .14\)), between day 5 and month 1 (11 of 59 [18.6%] vs 12 of 63 [19.0%]; difference, −0.4%; 95% CI, −14.4% to 13.6%; \(P = .96\) (Table 3), or at the month 1 visit (eTable 4 in Supplement 2).

**Specific Complications of SAE**

In the pSAE group, there were 5 minor complications: 3 reported at day 5 and 2 more reported at month 1. In the SURV group, there was 1 minor complication after urgent embolization (Table 3). There was no failure of embolization.

**Splenic Complications**

At the day 5 visit, there were significantly fewer SPAs among patients in the pSAE group compared with the SURV group (1 of 65 [1.5%] vs 8 of 65 [12.3%]; difference, −10.8%; 95% CI, −19.3% to −2.1%; \(P = .03\) (Table 3) as well as at the month 1 visit (eTable 4 in Supplement 2). Rates of SAIV and pseudocyst were not significantly different between the 2 groups (Table 3; eTable 4 and eTable 5 in Supplement 2). At the day 5 visit, there were significantly fewer secondary embolizations among patients in the pSAE group than in the SURV group (1 of 65 [1.5%] vs 19 of 65 [29.2%]; difference, −27.7%; 95% CI, −41.0% to −15.9%; \(P < .001\) (Table 3). During the whole follow-up period, there were 4 splenectomies (days 2, 6, and 44), for an overall rate of splenectomy of 3.3% (4 of 122). Rates of splenectomy were not significantly different between the pSAE and SURV groups (0 of 59 [0%] vs 4 of 63 [6.3%]; difference, −6.3%; 95% CI, −12.5% to −0.2%; \(P = .12\)).

**Other Complications**

Rates of other complications were not significantly different between the 2 groups (eTable 5 in Supplement 2). The occurrence of hemorrhagic syndrome (see definition in eTable 2 in Supplement 2) did not differ significantly between the pSAE

---

**Table 1**

| Noninclusion criteria except for mean hospital-to-home distance and circumstances of the unintentional injury. (Table 2). \(^2\)\(^2\)\(^9\)\(^3\)\(^3\) | \(P = .37\). The results of the sensitivity analysis are consistent with this conclusion (\(P = .16\). The 5 cases of failed spleen rescue occurred in 5 different centers (Table 3) without any failure of embolization.

---

**Figure 1. Study Flowchart**

- **Persons assessed for eligibility**
  - 663
  - 523 Ineligible
  - 140 Enrolled and randomized
  - 71 Assigned to pSAE
  - 69 Assigned to SURV
  - 70 Received pSAE
  - 69 Received surveillance
  - 4 Excluded owing to noninclusion criteria
  - 1 With no health insurance coverage
  - 1 OIS grade II according to expert radiologists
  - 1 OIS grade V and 100% devascularization according to expert radiologists
  - 1 With AIDS
  - 1 Withdrawing consent
  - 66 Retained in study
  - 1 Refused pSAE and withdrawn from study
  - 1 Patient died due to cranial injuries
  - 65 Patients assessed at day 5 visit
  - 5 Patients lost to follow-up
  - 60 Patients attended day 30 visit
  - 3 Had no CT scan at day 30 visit
  - 57 Included in primary end-point analysis
  - 50 Patients attended day 180 visit
  - 47 Patients attended day 180 visit

- **Primary End Point**
  - For the primary end point, the number of patients with at least 50% viable spleen detected on the CT scan at month 1 was not significantly different between the pSAE and SURV groups detected at day 5 (19 of 65 [29.2%] vs 27 of 65 [41.5%]; difference, −12.3%; 95% CI, −28.3% to 4.4%; \(P = .14\)), between day 5 and month 1 (11 of 59 [18.6%] vs 12 of 63 [19.0%]; difference, −0.4%; 95% CI, −14.4% to 13.6%; \(P = .96\) (Table 3), or at the month 1 visit (eTable 4 in Supplement 2).

- **Overall Mortality and Morbidity**
  - One patient from the SURV group died before the day 5 visit of cranial trauma (1 of 133 [0.8%]). There was no significant difference in the overall complication rate between the pSAE and SURV groups detected at day 5 (19 of 65 [29.2%] vs 27 of 65 [41.5%]; difference, −12.3%; 95% CI, −28.3% to 4.4%; \(P = .14\)), between day 5 and month 1 (11 of 59 [18.6%] vs 12 of 63 [19.0%]; difference, −0.4%; 95% CI, −14.4% to 13.6%; \(P = .96\) (Table 3), or at the month 1 visit (eTable 4 in Supplement 2).

- **Specific Complications of SAE**
  - In the pSAE group, there were 5 minor complications: 3 reported at day 5 and 2 more reported at month 1. In the SURV group, there was 1 minor complication after urgent embolization (Table 3). There was no failure of embolization.

- **Splenic Complications**
  - At the day 5 visit, there were significantly fewer SPAs among patients in the pSAE group compared with the SURV group (1 of 65 [1.5%] vs 8 of 65 [12.3%]; difference, −10.8%; 95% CI, −19.3% to −2.1%; \(P = .03\) (Table 3) as well as at the month 1 visit (eTable 4 in Supplement 2). Rates of SAIV and pseudocyst were not significantly different between the 2 groups (Table 3; eTable 4 and eTable 5 in Supplement 2). At the day 5 visit, there were significantly fewer secondary embolizations among patients in the pSAE group than in the SURV group (1 of 65 [1.5%] vs 19 of 65 [29.2%]; difference, −27.7%; 95% CI, −41.0% to −15.9%; \(P < .001\) (Table 3). During the whole follow-up period, there were 4 splenectomies (days 2, 6, and 44), for an overall rate of splenectomy of 3.3% (4 of 122). Rates of splenectomy were not significantly different between the pSAE and SURV groups (0 of 59 [0%] vs 4 of 63 [6.3%]; difference, −6.3%; 95% CI, −12.5% to −0.2%; \(P = .12\)).

- **Other Complications**
  - Rates of other complications were not significantly different between the 2 groups (eTable 5 in Supplement 2). The occurrence of hemorrhagic syndrome (see definition in eTable 2 in Supplement 2) did not differ significantly between the pSAE

---

**CT** indicates computed tomography; **OIS**. Organ Injury Scale; **pSAE**. prophylactic splenic arterial embolization; and **SURV**, surveillance with embolization only if necessary.

\(^a\) See eTable 1 in Supplement 2 for reasons for ineligibility.

\(^b\) Day 5 visit occurred between day 4 and day 8 after inclusion.
and SURV groups at day 5, nor did the necessity for transfu-
sion. In addition, there was no significant difference between
the pSAE and SURV groups in hemorrhagic complications oc-
curring after day 5 (Table 3; eTable 4 and eTable 5 in Supple-
ment 2). There was no significant difference between the pSAE
and SURV groups in the rates of thrombotic complications,
pleural effusion, and pulmonary infection detected at day 5
(Table 3), between day 5 and month 1 (Table 3), in the whole
first month (eTable 4 in Supplement 2), or between the month
1 and month 6 visits (eTable 5 in Supplement 2).

Failed in Each Group
Between day 0 and month 1, 2 of 65 patients (3.1%) in the pSAE
group had undergone urgent reembolization, and 21 of 65 pa-
tients (32.3%) in the SURV group had undergone splenic em-
bolization (eTable 4 in Supplement 2). The characteristics of
the 21 patients in the SURV group requiring a delayed inter-
vention (19 emergency reembolizations and 3 splenectomies [in-
cluding 1 after emergency embolization]) up to the day 5 visit
showed that splenic trauma of OIS grade 4 or higher was a risk
factor compared with OIS grade 3 (15 of 21 [71.4%] vs 9 of 44
[20.4%]; difference, 51.0% [95% CI, 24.8%-87.6%]; P < .001)
(eTable 6 in Supplement 2).

Length of Hospitalization
The median length of hospitalization was 11 days (IQR, 7-15
days). As shown in Figure 2, patients in the pSAE group had a
shorter median length of hospitalization compared with the

### Table 1. Baseline Characteristics of the Patients at Inclusion

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>pSAE (n = 66)</th>
<th>SURV (n = 67)</th>
<th>Total (N = 133)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>11 (16.7)</td>
<td>17 (25.4)</td>
<td>28 (21.1)</td>
</tr>
<tr>
<td>Male</td>
<td>55 (83.3)</td>
<td>50 (74.6)</td>
<td>105 (78.9)</td>
</tr>
<tr>
<td>Employed or student</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>18 (27.3)</td>
<td>16 (23.9)</td>
<td>34 (25.6)</td>
</tr>
<tr>
<td>Yes</td>
<td>48 (72.7)</td>
<td>50 (74.6)</td>
<td>98 (73.7)</td>
</tr>
<tr>
<td>Missing</td>
<td>0</td>
<td>1 (1.5)</td>
<td>1 (0.8)</td>
</tr>
<tr>
<td>Age, median (IQR), y</td>
<td>30 (22-42)</td>
<td>30 (23-48)</td>
<td>30 (23-47)</td>
</tr>
<tr>
<td>Distance between hospital and residence, median (IQR), km</td>
<td>45 (15-95)</td>
<td>30 (19-100)</td>
<td>30 (15-100)</td>
</tr>
<tr>
<td>Time from unintentional injury to enrollment in trial, median (IQR), h</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-23</td>
<td>29 (43.9)</td>
<td>42 (62.7)</td>
<td>71 (53.4)</td>
</tr>
<tr>
<td>24-48</td>
<td>37 (56.1)</td>
<td>25 (37.3)</td>
<td>62 (46.6)</td>
</tr>
<tr>
<td>Circumstances of unintentional injury</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Traffic</td>
<td>39 (59.1)</td>
<td>39 (58.2)</td>
<td>78 (58.6)</td>
</tr>
<tr>
<td>Domestic</td>
<td>3 (4.5)</td>
<td>5 (7.5)</td>
<td>8 (6.0)</td>
</tr>
<tr>
<td>Sport</td>
<td>16 (24.2)</td>
<td>16 (23.9)</td>
<td>32 (24.1)</td>
</tr>
<tr>
<td>Work</td>
<td>5 (7.6)</td>
<td>6 (9.0)</td>
<td>11 (8.3)</td>
</tr>
<tr>
<td>Other</td>
<td>3 (4.5)</td>
<td>1 (1.5)</td>
<td>4 (3.0)</td>
</tr>
<tr>
<td>OIS grade (after expert reread of CT scan images)*</td>
<td>37 (56.1)</td>
<td>43 (64.2)</td>
<td>80 (60.2)</td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>28 (42.4)</td>
<td>22 (32.8)</td>
<td>50 (37.6)</td>
</tr>
<tr>
<td>5</td>
<td>1 (1.5)</td>
<td>2 (3.0)</td>
<td>3 (2.3)</td>
</tr>
<tr>
<td>NISS, median (IQR)*</td>
<td>19 (12-25)</td>
<td>20 (13-29)</td>
<td>19 (13-27)</td>
</tr>
<tr>
<td>WOMAC score available before unintentional injury*</td>
<td>60 (90.9)</td>
<td>56 (83.6)</td>
<td>116 (87.2)</td>
</tr>
<tr>
<td>Missing</td>
<td>6 (9.1)</td>
<td>11 (16.4)</td>
<td>17 (12.8)</td>
</tr>
<tr>
<td>WOMAC score = 0 before unintentional injury*</td>
<td>46/60 (76.7)</td>
<td>46/56 (82.1)</td>
<td>92/116 (79.3)</td>
</tr>
</tbody>
</table>

**Abbreviations:** CT, computed tomography; IQR, interquartile range; NISS, New Injury Severity Score; OIS, Organ Injury Scale; pSAE, prophylactic splenic arterial embolization; SURV, surveillance, with embolization only if necessary; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.

*The OIS from the American Association for the Surgery of Trauma is a widely used anatomic score. It takes into account the type of damage (eg, hematoma or tearing), the localization in the splenic gland (eg, intraparenchymal or subcapsular), and the percentage of devascularized tissue. Grade 3 includes subcapsular hematoma of more than 50% of the spleen surface, rupture, spreading, or bleeding and/or intraparenchymal hematoma evolutive or diameter greater than 5 cm and/or capsular tear with a depth greater than 3 mm or that involves trabecular vessels. Grade 4 includes ruptured hematoma, lesion reaching segmental or hilar vessels, or more than 25% devascularized spleen. Grade 5 corresponds to complete splenic fragmentation.

*The NISS is a widely used anatomic score giving an overall score for the anatomical lesions of a person with multiple traumas. Each organ involved is scored according to the OIS from 1 (mild) to 5 (total destruction or devascularization of the organ) according to the criteria of the American Association for the Surgery of Trauma. The NISS is calculated from the OIS of the 3 most serious lesions as follows: NISS = a² + b² + c² (eg, a patient with a cerebral contusion rated OIS = 3, a spleen fracture rated OIS = 4, and minor hepatic injury rated OIS = 2 will have an NISS of 9 + 16 + 4 = 29). A trauma is considered severe when the NISS is 15 or more. 30

* The WOMAC self-administered questionnaire uses a Likert scale with 5 possible answers (none = 0, minimum = 1, moderate = 2, severe = 3, and extreme = 4) to several questions about physical functional impairment, pain, and stiffness. The minimum score (0) corresponds to no affliction and the maximum score (96) corresponds to severe distress and disability.
Activity Score
There was no statistical difference between the pSAE and the SURV groups in the median WOMAC score before the unintentional injury (0 [IQR, 0–0] vs 0 [IQR, 0–0]; P = .38), at month 1 (4 [IQR, 0–13] vs 4 [IQR, 0–26]; P = .51), and at month 6 (0 [IQR, 0–7] vs 0 [IQR, 0–6.5]; P = .63) (eTable 7 in Supplement 2).

Length of Time Off Work or Studies
At month 1, there was no significant difference between the pSAE and SURV groups in return to work or studies (6 of 43 [14.0%] vs 5 of 45 [11.1%]; difference, 2.9%; 95% CI, –11.2% to 16.8%; P = .69). There was also no significant difference between the 2 groups in the total time off work or studies at 6 months (27 of 36 [75.0%] vs 22 of 36 [61.1%]; difference, 13.9%; 95% CI, –8.2% to 36.2%; P = .21) (eTable 8 in Supplement 2).

Discussion
In this randomized clinical trial that enrolled selected hemodynamically stable patients presenting with spleen trauma at high risk of rupture, immediate pSAE did not provide any significant difference in the spleen rescue rate compared with
SURV (98.2% vs 93.3%), with a rate of spleen rescue in the SURV group of 93.3% (56 of 60 patients) at 1 month that was much higher than expected from the data in the literature when we designed the trial. The predominant feature of our study was that 32.3% of patients in the SURV group required embolization or splenectomy, with the only risk factor being the severity of the splenic trauma, because 71.4% of patients with splenic trauma of OIS grade 4 or higher required embolization or splenectomy. Patients in the pSAE group had statistically fewer occurrences of SPA (in line with a recent retrospective study), seen both at day 5 and at 1 month, as well as significantly shorter lengths of hospitalization.

The precise assessment of the risk of secondary spleen rupture in a patient with spleen trauma who is stable with no active leakage of contrast medium or SPA or SAVF is crucial to reducing the rate of splenectomies for trauma. In this study, we assessed these criteria using the initial CT scan. Several publications have highlighted the difficulty of comparing studies with imprecise CT criteria, particularly regarding the severity of spleen lesion(s) and the volume of the

<table>
<thead>
<tr>
<th>Table 3. Complications Reported at Day 5 Visit and at Month 1 Visit</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type of complication</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Need for splenic embolization</td>
</tr>
<tr>
<td>Due to SAE procedure</td>
</tr>
<tr>
<td>Hematoma on femoral access</td>
</tr>
<tr>
<td>Thrombosis on femoral access</td>
</tr>
<tr>
<td>Aneurysm on femoral access</td>
</tr>
<tr>
<td>Allergy to contrast agent</td>
</tr>
<tr>
<td>Kidney insufficiency</td>
</tr>
<tr>
<td>Arteriovenous fistula</td>
</tr>
<tr>
<td>Pseudoaneurysm</td>
</tr>
<tr>
<td>Pseudocyst</td>
</tr>
<tr>
<td>Hemorrhagic</td>
</tr>
<tr>
<td>Decrease in hemoglobin &gt;3 g/dL with an identified bleeding site or a decrease in hemoglobin &gt;4 g/dL without an identified bleeding site</td>
</tr>
<tr>
<td>Transfusion</td>
</tr>
<tr>
<td>No. of packed RBC units transfused, median (IQR)</td>
</tr>
<tr>
<td>Infectious</td>
</tr>
<tr>
<td>≥1 Infectious complications</td>
</tr>
<tr>
<td>Septicemia</td>
</tr>
<tr>
<td>Pancreatic</td>
</tr>
<tr>
<td>Pancreatitis</td>
</tr>
<tr>
<td>Thrombotic</td>
</tr>
<tr>
<td>Thrombosis of splenoportal trunk</td>
</tr>
<tr>
<td>Phlebitis</td>
</tr>
<tr>
<td>Pulmonary embolism</td>
</tr>
<tr>
<td>Pulmonary</td>
</tr>
<tr>
<td>Pleural effusion</td>
</tr>
<tr>
<td>Thoracic drain if pleural effusion</td>
</tr>
<tr>
<td>Pulmonary infection</td>
</tr>
<tr>
<td>≥1 Complications (all)</td>
</tr>
</tbody>
</table>

Abbreviations: IQR, interquartile range; NA, not applicable; pSAE, prophylactic splenic arterial embolization; RBC, red blood cell; SAE, splenic arterial embolization; SURV, surveillance, with embolization only if necessary.

SI conversion factor: To convert hemoglobin to grams per liter, multiply by 10.0.

*Events occurring between day 0 and day 5 visits (where the day 5 visit occurred between day 4 and day 8 after inclusion).  
*Events occurring between day 5 visit and month 1 visit.  
*For 79 patients.  
*For 20 patients.
Proximal splenic artery embolization decreases the perfusion of the radiologists and the embolization techniques used. \(^{24,26}\) The embolization complication rate in our trial was low, less than 10%. Only 1 case of splenic necrosis involving more than half the volume of the gland occurred in the pSAE group. In the literature, there are significant variations in the rate of specific complications of embolization, \(^{11,19}\) which can be attributed to the degree of expertise of the radiologists and the embolization techniques used. Proximal splenic artery embolization decreases the perfusion pressure in the spleen and allows for the viability of the spleen to be maintained via collateral pathways. Distal embolization can be used in cases of focal injury. \(^{41}\) In terms of efficacy, the results seem comparable. \(^{42}\) A meta-analysis by Schnüriger et al \(^{47}\) showed that a recurrence of bleeding was the most common reason for failure and did not differ statistically between the techniques used. In our trial, we used a maximum 6F catheter and rigid coils of 0.089 cm (0.035 inches) for pSAE, which reduced the risk of complications in terms of vascular access. The recommended technique of proximal or combined embolization, the avoidance of microcoils, and the prohibition of the use of glue, gelatin fragments, or microparticles made it possible to avoid extensive splenic necrosis.

### Limitations

There were several limitations to our trial. We cannot exclude the possibility of imbalances in unknown confounders between the evaluable groups. Other limitations were the absence of an individual calculation of the irradiated volume to which patients in the 2 groups were exposed and no medico-economic comparison of the 2 strategies. We acknowledge that the data available in the literature when we designed the study in 2012 led us to underestimate the sample size. Another limitation was the possibility that, outside the context of a clinical trial, the surveillance of posttrauma patients was not as rigorous as it should have been.

### Conclusions

For hemodynamically stable patients with splenic trauma at high risk of rupture, there was no significant difference in the rates of splenic rescue and complications or in their effects on activities between immediate pSAE and SURV with SAE performed only if necessary. A significant proportion of patients in the SURV group needed SAE (in particular, those with higher OIS grade splenic injuries). Performing control CT scans on about day 5 and day 30, with SAE if necessary, seems to provide a good rate of spleen salvage for trauma patients at high risk of splenic rupture, but the practice needs to be validated in further studies.
Effect of Prophylactic Embolization on Trauma Patients at High Risk of Splenectomy

Original Investigation Research

REFERENCES


How Should the SPLASH Trial Inform the Care of Patients With Blunt Splenic Trauma?

Shah-Jahan Dodwad, DO; Michael W. Wandling, MD, MS; Lillian S. Kao, MD, MS

Management of blunt splenic injury has evolved over time, with nonoperative management being the recommended initial management strategy among hemodynamically stable adult patients without peritonitis. Although advances have resulted in the improved success of nonoperative management and in the identification of patients at high risk for splenic failure, questions remain regarding the optimal role of angioembolization for these patients. In this issue of JAMA Surgery, Arvieux et al randomized 140 patients with grade 3 or higher blunt splenic injuries to prophylactic splenic angioembolization or surveillance with as-needed angioembolization in the study for Splenic Arterial Embolization to Avoid Splenectomy (SPLASH) trial. Overall, 96% patients had a viable spleen at 1 month, with no difference in splenic preservation between the 2 groups. Approximately one-third of patients in the surveillance group required either splenectomy or embolization, with the only risk factor for splenic failure being the severity of the splenic injury. The surveillance group experienced significantly more pseudoaneurysms and a longer median length of stay than the prophylactic splenic angioembolization group. There were no differences in patient-reported outcomes of functional activity and time off work or studies.

The authors should be commended for performing a multicenter randomized clinical trial to address the controversy of routine angioembolization for patients at high risk of splenic rupture. The high rate of splenic salvage with nonoperative management, regardless of angioembolization strategy, is reassuring. Although the splenectomy rate might have been a more clinically meaningful primary outcome, the trial would have required significantly more patients and a longer time period to be adequately powered. As it is, the trial was likely underpowered to determine whether there was a difference in complications. Nonetheless, the trial minimizes bias in estimating the relative risks and benefits of the 2 strategies.

Among trauma patients, outpatient follow-up and surveillance are often challenging, so offering a potentially definitive therapy with routine prophylactic angioembolization is appealing. On the other hand, although angioembolization-related complications were rare in the SPLASH trial, bleeding and splenic abscesses are accepted major complications. There are also barriers to the widespread adoption of routine prophylactic angioembolization. First, poor interrater reliability in grading splenic injuries could result in the improper selection of patients for angioembolization. Second, interventional radiology may not be available or as effective and safe at all hospitals.

The SPLASH trial ultimately does not recommend one management strategy over another but concludes that both prophylactic angioembolization and surveillance are defensible strategies for patients with blunt trauma at high risk for splenic rupture. However, it does provide a starting point for discussions with patients to engage in shared decision-making. Patients who are at high risk for not being able to follow up or those with a grade 4 or 5 injury may wish to consider more seriously prophylactic angioembolization. In the meantime, the SPLASH trial is a refreshing and welcome addition to the observational studies informing the care of patients with blunt trauma.

ARTICLE INFORMATION

Author Affiliations: Division of Acute Care Surgery, McGovern Medical School at University of Texas Health Science Center at Houston.

Corresponding Author: Lillian S. Kao, MD, MS, Division of Acute Care Surgery, McGovern Medical School at University of Texas Health Science Center at Houston, 6431 Fannin St, MSB 4.264, Houston, TX 77030 (lillian.s.kao@uth.tmc.edu).


Conflict of Interest Disclosures: None reported.

REFERENCES


jamasurgery.com  JAMA Surgery Published online September 16, 2020 E1

© 2020 American Medical Association. All rights reserved.